On May 6th, Weng Yuyao, Director of the Fujian Provincial Department of Industry and Information Technology, along with his delegation, visited Maxin Company for research and guidance. They were warmly accompanied by leaders including Fan Xueshuang, Deputy Secretary of the Party Working Committee and Director of the Management Committee of the High-tech Zone.
CompanyDeputy General Manager Wang Jianmin、Yang Qinghaialso participated in this event.
The research group arrived at the Maxin exhibition hall. Deputy General Managers Wang and Yang first welcomed the leaders and provided a detailed introduction to the company’s development history, main business, andindependent innovationother aspects. The research group expressedfull recognitionregarding the various development achievements of Maxin Company andencouraging Maxin personnel to continue their efforts and achieve greater success in the future.
Visiting Maxin Laboratory
Guided enthusiastically by the company’s leadership, the research group also visited Maxin Company’s laboratory with great interest. Deputy General Manager Yang introduced to Director WengMaxin’s product quality control system, andthe application of immunohistochemistry technology in pathological diagnosis,othersituations.。
Director Weng stated that for high-quality enterprise development, product quality stability is an important booster, especially for biopharmaceutical companies, which bear significant responsibility as they relate to people’s life and health.
During the research activity, the research group held a special symposium at Maxin Company. Company leaders reported to the research group on the enterprise’s operational status and the difficulties and pain points encountered during its development process. The research group indicated that this research visit was to respond to the enterprise’s development needs and coordinate solutions to its problems.promote the high-quality development of the biopharmaceutical industry in the High-tech Zone,They hoped that Maxin, as an outstanding representative of high-tech enterprises, would actively provide suggestions and advice on the development direction of the biopharmaceutical industry, toand contribute to revitalizing the national biopharmaceutical industry.。
Company leaders stated that under the long-termcare and supportof government leaders at all levels, Maxin Company has remained true to its original aspirations, committed to independent innovation, continuously enhanced its core competitiveness, and achieved significant development in the in vitro diagnostics industry.In the future, they will strive to seize the opportunities of the times, demonstrate Maxin’s responsibility,not to disappoint the expectations and care of superior leaders,focus on building the enterprise well, for the nation’sbiopharmaceutical industryand add luster.
